Global Variations and Changes in Patterns of Infectious Uveitis

2017 ◽  
pp. 1-7
Author(s):  
François Willermain ◽  
Yves Van Laethem ◽  
Laure Caspers
Keyword(s):  
Infectious Uveitis

Changes in temperature of the ocular surface in the projection of the ciliary body in the early stages of induced non-infectious uveitis in rabbits

2020 ◽  
Vol 86 (3) ◽  
pp. 47-52
Author(s):  
O. Dorokhova ◽  
◽  
O. Zborovska ◽  
Meng Guanjun ◽  
◽  
...  
Keyword(s):  
Ocular Surface ◽  
Ciliary Body ◽  
Early Stages ◽  
Infectious Uveitis

Management of repository corticotropin injection therapy for non‐infectious uveitis: a Delphi study

2021 ◽  
Author(s):  
Quan Dong Nguyen ◽  
Stephen D. Anesi ◽  
Saradha Chexal ◽  
David S. Chu ◽  
Pouya N. Dayani ◽  
...  
Keyword(s):  
Delphi Study ◽  
Injection Therapy ◽  
Infectious Uveitis

Prevalence and incidence rates and treatment patterns of non-infectious uveitis in Japan: real-world data using a claims database

2021 ◽  
Author(s):  
Akihiko Umazume ◽  
Nobuyuki Ohguro ◽  
Annabelle A. Okada ◽  
Kenichi Namba ◽  
Koh-Hei Sonoda ◽  
...  
Keyword(s):  
Real World ◽  
Incidence Rates ◽  
Treatment Patterns ◽  
Real World Data ◽  
Claims Database ◽  
World Data ◽  
Infectious Uveitis

scholarly journals Role of interferon gamma release assay in the diagnosis and management of Mycobacterium tuberculosis-associated uveitis: a review

2021 ◽  
Vol 6 (1) ◽  
pp. e000663
Author(s):  
Samra Rahman ◽  
Muhammad Irfan ◽  
M A Rehman Siddiqui
Keyword(s):  
Interferon Gamma ◽  
Interferon Gamma Release Assay ◽  
Limited Evidence ◽  
Ocular Tuberculosis ◽  
Diagnosis And Management ◽  
Pubmed Database ◽  
Interferon Gamma Release Assays ◽  
Infectious Uveitis ◽  
Release Assay

Tuberculosis (TB)-associated uveitis is a common cause of infectious uveitis in the developing world. Diagnosis of TB uveitis remains a challenge. The role of interferon gamma release assays (IGRAs) is uncertain. Herein we summarise the available literature on the utility of IGRAs in the diagnosis and management of TB uveitis. We searched PubMed database from 1 August 2010 to 31 July 2020 using the following keywords alone and in combination: ‘interferon-gamma release assay’, ‘QuantiFERON’, ‘T-SPOT.TB’, ‘TB uveitis’, ‘serpiginous like choroiditis’, ‘tuberculoma’, ‘TB vasculitis’, ‘TB panuveitis’ and ‘ocular tuberculosis’. Data from 58 relevant studies were collated. The review is focused on currently marketed versions of IGRA tests: QuantiFERON-TB Gold In-Tube assay, QuantiFERON-TB Gold Plus assay (QFT-Plus) and T-SPOT.TB. We found limited evidence regarding the diagnostic utility of IGRA in patients with uveitis. No study was identified evaluating the newer QFT test—the QFT-Plus—in patients with uveitis. Similarly, there is lack of data directly comparing QFT-Plus with T-SPOT.TB specifically for the diagnosis of TB uveitis.

Uveitis in Siriraj Hospital: pattern differences between immune-related uveitis and infectious uveitis in a university-based tertiary care hospital

2017 ◽  
Vol 38 (2) ◽  
pp. 673-678 ◽  
Author(s):  
Nattaporn Tesavibul ◽  
Sutasinee Boonsopon ◽  
Pitipol Choopong ◽  
Sujintana Tanterdtham
Keyword(s):  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Care Hospital ◽  
Siriraj Hospital ◽  
Infectious Uveitis

scholarly journals Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis

Eye ◽  
2021 ◽  
Author(s):  
Carlos Pavesio ◽  
Carsten Heinz
Keyword(s):  
Cataract Surgery ◽  
Treatment Strategies ◽  
Standard Of Care ◽  
Fluocinolone Acetonide ◽  
Posterior Segment ◽  
Recurrence Rates ◽  
Intravitreal Implant ◽  
Infectious Uveitis ◽  
Dose Corticosteroid ◽  
Fellow Eyes

Abstract Background Prevention of non-infectious uveitis of the posterior segment (NIU-PS) recurrence using 0.2 μg/day fluocinolone acetonide implant (FAi) was assessed over 3 years (NCT01694186). Outcomes for FAi-treated and fellow eyes with NIU-PS were compared, to evaluate FAi versus conventional treatment strategies. Methods Eligible subjects had >1-year recurrent NIU-PS history and either ≥2 separate recurrences requiring treatment, or corticosteroid therapy (systemic or ocular) in the 12 months preceding study entry. Bilateral disease was present and analysed in 59/87 FAi-treated participants. Recurrence rates, best-corrected visual acuity (BCVA) changes, cataract surgery, intraocular pressure (IOP) events and adjunctive medication use were compared for FAi-treated and fellow eyes. Results Over 36 months, more FAi-treated than fellow eyes remained recurrence-free (28.8% vs. 5.1%, P = 0.001; mean 1.9 vs. 4.7 recurrences, respectively, P < 0.0001). FAi-treated eyes gained +9.6 letters BCVA, versus a loss of −4.4 in fellow eyes (P < 0.0001). Systemic medications were given to 42.4% of subjects. Intra/periocular adjunctive injections were lower in FAi-treated than fellow eyes (20.3% vs. 66.1%, P < 0.0001); topical corticosteroid use was also lower in FAi-treated than fellow eyes (27.1% vs 52.5%, P = 0.0041). IOP-related events occurred at similar rates in both FAi-treated and fellow eyes, excepting IOP-lowering surgery (5.1% vs. 15.3%, respectively; P = 0.1251). Cataract surgery occurred in 72.0% of FAi-treated and 37.0% of fellow eyes. Conclusions In subjects with bilateral NIU-PS, continuous, low-dose corticosteroid with 0.2 μg/day FAi reduced recurrence and adjunctive medication requirements, and improved vision over 36 months, providing greater protection against ocular inflammation than a reactive approach using standard of care.

Clinical Features of Infectious Uveitis in the Pediatric Population in Colombia

2021 ◽  
Author(s):  
Daniela Roca ◽  
Hernán A. Rios ◽  
Diana A. Cortés ◽  
Shirley M. Rosenstiehl ◽  
Vanessa Carpio ◽  
...  
Keyword(s):  
Clinical Features ◽  
Pediatric Population ◽  
Infectious Uveitis
Sign in / Sign up

Export Citation Format

Share Document